SurModics Cut to Neutral Zacks.com We are also concerned about factors such as partner Johnson & Johnson's (JNJ) decision to stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents. SurModics received royalties on sales of the product. ... |
